The global c-reactive protein testing market size was estimated to be USD 2.28 billion in 2023 and is expected to reach at USD 4.17 billion by 2034 with a CAGR of 5.63% during the forecast period 2024-2034. Rising prevalence of cardiovascular diseases, growing adoption of point-of-care devices, increasing government initiatives for the implementation of point-of-care screening, surge in development of innovative techniques in C-reactive protein (CRP) testing, rising prevalence of endometriosis in women, growing demand for healthcare services, increasing advancements in technology used for measuring CRP levels in patients, and surge in launch of advanced tests are the primary drivers of market expansion.
Surge in launch of advanced tests is predicted to boost the market growth during the forecast period. C-reactive protein is regarded as a general indicator of inflammation and serves a crucial role in forecasting an individual's likelihood of experiencing a heart attack or stroke. Furthermore, the concentration of C-reactive protein in the bloodstream aids in identifying a range of chronic illnesses, including cancer, cardiovascular conditions, rheumatoid arthritis, and more. Therefore, it provides an opportunity for market players to develop innovating testing products. For instance, in July 2022, Swiss medical technology firm, Bloom Diagnostics, has introduced the Bloom Inflammation Test, designed to identify and measure CRP levels accurately. This test is compatible with the Bloom systems.
By product, reagents & kits was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to surge in number of patients undergoing C-reactive protein testing for various diseases, increasing approvals by regulatory bodies, and rising launch of new products. For instance, in February 2022, Aidian, a company specializing in diagnostic tests and testing solutions based in Finland, has launched the QuikRead go weCRP & wrCRP+Hb kits. These kits provide two consistent outcomes, measuring a broad spectrum of CRP and Hb levels, all from a single sample in a single analysis. Additionally, instruments is predicted to grow at fastest CAGR during the forecast period owing to the rising approvals of medical instruments by regulatory bodies and increasing technological advancements.
By assay type, immunoturbidimetric assays was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the increasing development & accessibility of cost-efficient automated immunoturbidimetric assays that offer high sensitivity for measuring a wide range of CRP levels, rising adoption of these tests in clinical biochemistry for routine analysis of CRP & high-sensitivity CRP, growing research & development activities regarding immunoturbidimetric assays, surge in technological advances in immunoturbidimetric assays, and rising approval of immunoturbidimetric assays. For instance, in January 2022, LumiraDx, a company specializing in advanced point-of-care diagnostic solutions, has received CE Marking for its C-reactive protein (CRP) Test. This CRP Test by LumiraDx is a compact, portable, fully automated microfluidic immunoassay test designed for the precise measurement of C-reactive protein levels, providing results in just four minutes. Additionally, ELISA is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer, rising adoption of ELISA tests for cancer detection, growing demand for these tests, and urge in number of establishments of the facilities providing the test.
By detection range, hs-CRP was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the increasing utilization for the detection of inflammation, growing number of research studies on inflammatory markers, rising demand of biomarker for determining the pathogenesis of rheumatoid arthritis, and surge in approvals by regulatory bodies. For instance, in December 2022, Siemens Healthcare Diagnostics Products GmbH has obtained 510(k) clearance from the U.S. FDA for its CardioPhase hs-CRP prognostic test. Additionally, conventional CRP is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for conventional CRP and increasing technological advancements.
By disease, cardiovascular diseases (CVD) was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the growing in the prevalence of CVDs, increasing adoption of CRP testing for the detection of cardiovascular diseases. Additionally, cancer is predicted to grow at fastest CAGR during the forecast period owing the rising adoption of point-of-care (POC) testing solutions to aid in cancer management, increasing demand for CRP testing products & services, growing research & development activities for the development of an innovative therapy option based on CRP, and surge in launch of new products. For instance, in February 2023, Qlife Holdings AB has introduced the Egoo CRP test in Sweden through a gentle rollout. Following this initial release, the company intends to proceed with the application process for obtaining the CE mark.
By end-user, hospitals was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the growing adoption of CRP testing in hospitals, rising prevalence of CVDs & cancer-related infections, surge in number of hospital visits, leading to an increased demand for CRP testing kits, and increasing regulatory approvals. For instance, in November 2022, FDA approval has been granted to ProciseDx Inc. for both its CRP test and the ProciseDx instrument. The CRP test offered by ProciseDx, known as the Precise CRP test, empowers medical practitioners to swiftly and precisely gauge CRP levels in patient serum, producing results in under five minutes. Furthermore, ProciseDx aims to attain more FDA clearances for supplementary tests in the year 2023. Additionally, clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of point-of-care CRP testing, surge in availability & cost-effectiveness of CRP testing, growing demand for rapid & accurate diagnostic testing, rising governments' investment & financial support to encourage the adoption of point-of-care CRP testing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing product launches, rising prevalence of cardiovascular diseases, growing technological advancements, and surge in collaborations within market players for the development of advanced solutions. For instance, in March 2022, Novo Integrated Sciences, Inc. and Boditech Med Inc. have entered into a Memorandum of Understanding (MoU) to introduce and implement the IVD solutions and technologies of Boditech Med Inc. in the North American region. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of product launches for CRP testing, growing geriatric population, increasing adoption of CRP testing in hospitals, rising prevalence of cardiovascular diseases, and surge in launch of new products. For instance, in November 2022, In India, LumiraDx Healthcare Private Limited has unveiled a CRP point-of-care antigen test known for its exceptional sensitivity. This test is intended for use across diverse clinical environments and seeks to lower the overuse of antibiotics, consequently playing a role in mitigating the emergence of antimicrobial resistance.
Surge in launch of advanced tests is predicted to boost the market growth during the forecast period. C-reactive protein is regarded as a general indicator of inflammation and serves a crucial role in forecasting an individual's likelihood of experiencing a heart attack or stroke. Furthermore, the concentration of C-reactive protein in the bloodstream aids in identifying a range of chronic illnesses, including cancer, cardiovascular conditions, rheumatoid arthritis, and more. Therefore, it provides an opportunity for market players to develop innovating testing products. For instance, in July 2022, Swiss medical technology firm, Bloom Diagnostics, has introduced the Bloom Inflammation Test, designed to identify and measure CRP levels accurately. This test is compatible with the Bloom systems.
By product, reagents & kits was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to surge in number of patients undergoing C-reactive protein testing for various diseases, increasing approvals by regulatory bodies, and rising launch of new products. For instance, in February 2022, Aidian, a company specializing in diagnostic tests and testing solutions based in Finland, has launched the QuikRead go weCRP & wrCRP+Hb kits. These kits provide two consistent outcomes, measuring a broad spectrum of CRP and Hb levels, all from a single sample in a single analysis. Additionally, instruments is predicted to grow at fastest CAGR during the forecast period owing to the rising approvals of medical instruments by regulatory bodies and increasing technological advancements.
By assay type, immunoturbidimetric assays was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the increasing development & accessibility of cost-efficient automated immunoturbidimetric assays that offer high sensitivity for measuring a wide range of CRP levels, rising adoption of these tests in clinical biochemistry for routine analysis of CRP & high-sensitivity CRP, growing research & development activities regarding immunoturbidimetric assays, surge in technological advances in immunoturbidimetric assays, and rising approval of immunoturbidimetric assays. For instance, in January 2022, LumiraDx, a company specializing in advanced point-of-care diagnostic solutions, has received CE Marking for its C-reactive protein (CRP) Test. This CRP Test by LumiraDx is a compact, portable, fully automated microfluidic immunoassay test designed for the precise measurement of C-reactive protein levels, providing results in just four minutes. Additionally, ELISA is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cancer, rising adoption of ELISA tests for cancer detection, growing demand for these tests, and urge in number of establishments of the facilities providing the test.
By detection range, hs-CRP was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the increasing utilization for the detection of inflammation, growing number of research studies on inflammatory markers, rising demand of biomarker for determining the pathogenesis of rheumatoid arthritis, and surge in approvals by regulatory bodies. For instance, in December 2022, Siemens Healthcare Diagnostics Products GmbH has obtained 510(k) clearance from the U.S. FDA for its CardioPhase hs-CRP prognostic test. Additionally, conventional CRP is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for conventional CRP and increasing technological advancements.
By disease, cardiovascular diseases (CVD) was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the growing in the prevalence of CVDs, increasing adoption of CRP testing for the detection of cardiovascular diseases. Additionally, cancer is predicted to grow at fastest CAGR during the forecast period owing the rising adoption of point-of-care (POC) testing solutions to aid in cancer management, increasing demand for CRP testing products & services, growing research & development activities for the development of an innovative therapy option based on CRP, and surge in launch of new products. For instance, in February 2023, Qlife Holdings AB has introduced the Egoo CRP test in Sweden through a gentle rollout. Following this initial release, the company intends to proceed with the application process for obtaining the CE mark.
By end-user, hospitals was the highest revenue-grossing segment in the global c-reactive protein testing market in 2023 owing to the growing adoption of CRP testing in hospitals, rising prevalence of CVDs & cancer-related infections, surge in number of hospital visits, leading to an increased demand for CRP testing kits, and increasing regulatory approvals. For instance, in November 2022, FDA approval has been granted to ProciseDx Inc. for both its CRP test and the ProciseDx instrument. The CRP test offered by ProciseDx, known as the Precise CRP test, empowers medical practitioners to swiftly and precisely gauge CRP levels in patient serum, producing results in under five minutes. Furthermore, ProciseDx aims to attain more FDA clearances for supplementary tests in the year 2023. Additionally, clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of point-of-care CRP testing, surge in availability & cost-effectiveness of CRP testing, growing demand for rapid & accurate diagnostic testing, rising governments' investment & financial support to encourage the adoption of point-of-care CRP testing.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing product launches, rising prevalence of cardiovascular diseases, growing technological advancements, and surge in collaborations within market players for the development of advanced solutions. For instance, in March 2022, Novo Integrated Sciences, Inc. and Boditech Med Inc. have entered into a Memorandum of Understanding (MoU) to introduce and implement the IVD solutions and technologies of Boditech Med Inc. in the North American region. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of product launches for CRP testing, growing geriatric population, increasing adoption of CRP testing in hospitals, rising prevalence of cardiovascular diseases, and surge in launch of new products. For instance, in November 2022, In India, LumiraDx Healthcare Private Limited has unveiled a CRP point-of-care antigen test known for its exceptional sensitivity. This test is intended for use across diverse clinical environments and seeks to lower the overuse of antibiotics, consequently playing a role in mitigating the emergence of antimicrobial resistance.
Segmentation: C-Reactive Protein Testing Market Report 2022 - 2033
C-Reactive Protein Testing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments
- Reagents & Kits
C-Reactive Protein Testing Market Analysis & Forecast by Assay Type 2023 - 2034 (Revenue USD Bn)
- Chemiluminescence Immunoassay (CLIA)
- Immunoturbidimetric Assay
- ELISA
- Others
C-Reactive Protein Testing Market Analysis & Forecast by Detection Range 2023 - 2034 (Revenue USD Bn)
- Conventional CRP
- cCRP
- hs-CRP
C-Reactive Protein Testing Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Rheumatoid Arthritis
- Cardiovascular Diseases
- Lupus
- Endometriosis
- Cancer
- Inflammatory Bowel Disease
- Others
C-Reactive Protein Testing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home
- Laboratories
- Clinics
- By Entity
- By Settings
- Assisted Living Healthcare Facilities
- Hospitals
- Others
C-Reactive Protein Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. C-Reactive Protein Testing Market: Product Estimates & Trend Analysis
8. C-Reactive Protein Testing Market: Assay Type Estimates & Trend Analysis
9. C-Reactive Protein Testing Market: Detection Range Estimates & Trend Analysis
10. C-Reactive Protein Testing Market: Disease Estimates & Trend Analysis
11. C-Reactive Protein Testing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America C-Reactive Protein Testing Market
14. Europe Global C-Reactive Protein Testing Market
15. Asia Pacific Global C-Reactive Protein Testing Market
16. Latin America Global C-Reactive Protein Testing Market
17. MEA Global C-Reactive Protein Testing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd.
- Aidian
- Danaher
- Abbott
- HORIBA Ltd
- Getein Biotech Inc.
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Zoetis
- Quest Diagnostics
- Boditech Med Inc.
- Ortho Clinical Diagnostics
- Randox Laboratories Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.28 Billion |
| Forecasted Market Value ( USD | $ 4.17 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
